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Abstract
SNP rs7903146 in the Wnt pathway’s TCF7L2 gene is the variant most significantly associ-
ated with type 2 diabetes to date, with associations observed across diverse populations.
We sought to determine whether variants in other Wnt pathway genes are also associated
with this disease. We evaluated 69 genes involved in the Wnt pathway, including TCF7L2,
for associations with type 2 diabetes in 2632 African American cases and 2596 controls
from the Black Women’s Health Study. Tag SNPs for each gene region were genotyped on
a custom Affymetrix Axiom Array, and imputation was performed to 1000 Genomes Phase 3
data. Gene-based analyses were conducted using the adaptive rank truncated product
(ARTP) statistic. The PSMD2 gene was significantly associated with type 2 diabetes after
correction for multiple testing (corrected p = 0.016), based on the nine most significant single
variants in the +/- 20 kb region surrounding the gene, which includes nearby genes EIF4G1,
ECE2, and EIF2B5. Association data on four of the nine variants were available from an
independent sample of 8284 African American cases and 15,543 controls; associations
were in the same direction, but weak and not statistically significant. TCF7L2 was the only
other gene associated with type 2 diabetes at nominal p <0.01 in our data. One of the three
variants in the best gene-based model for TCF7L2, rs114770437, was not correlated with
the GWAS index SNP rs7903146 and may represent an independent association signal
seen only in African ancestry populations. Data on this SNP were not available in the replica-
tion sample.
Introduction
African American women experience a greater burden from type 2 diabetes compared to U.S.
women of European ancestry. Incidence in African American women is more than twice that
in U.S. white women, with >50% of this excess rate remaining after adjustment for known
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type 2 diabetes risk factors including body mass index (BMI) [1]. In addition, African Ameri-
cans with diabetes have poorer glycemic control [2] and an increased risk of diabetic complica-
tions and mortality [3] compared to whites. Given these racial disparities, it is critical that
more studies be conducted to investigate the etiology of type 2 diabetes in African American
women.
More than 75 genetic loci for type 2 diabetes have been discovered in European, Asian, and
Mexican ancestry populations [4–7], while only three novel variants have been discovered
in genome-wide association studies (GWAS) of African ancestry (AA) populations [8,9].
Attempts to replicate type 2 diabetes associations from European samples in AA populations
suggest that a majority of the variants show associations in the same direction in AA samples
[8,10–13]. However, only a few loci have achieved statistical significance in replication
attempts. Most notable is SNP rs7903146 in the TCF7L2 gene, the variant most significantly
associated with type 2 diabetes to date.
TCF7L2 encodes a transcription factor that plays an important role in the Wnt signaling
pathway, and its risk alleles appear to be associated with impaired insulin secretion / beta-cell
function [14,15]. The Wnt pathway is one of the cell’s most important developmental and
growth regulatory mechanisms [16], critical in determining cell fate, proliferation, polarity,
and cell death during embryonic development, and also in adult tissue homeostasis. Abnor-
malities in Wnt signaling have been implicated in a variety of human diseases [17].
The Wnt signaling pathway is actually a group of signal transduction pathways: the canoni-
cal Wnt pathway leads to the regulation of gene transcription, and multiple non-canonical
Wnt pathways regulate the cell’s cytoskeleton and calcium stores [17]. All Wnt signaling path-
ways are initiated by the binding of a Wnt ligand to a Frizzled family transmembrane receptor.
In the case of the canonical pathway, the resulting intracellular signaling cascade leads to the
inactivation of a β-catenin destruction complex [18]. β-catenin thus avoids destruction and
translocates from the cytoplasm to the nucleus where it interacts with TCF7L2 and other tran-
scription factors, replacing transcriptional repressors and recruiting coactivators [17,19].
Genes involved in the β-catenin destruction complex may influence susceptibility to type 2
diabetes, given the critical role this complex plays in Wnt signal transduction with the resulting
downstream effects on diabetes locus TCF7L2. AA as well as European individuals may be
affected, considering that the TCF7L2 / diabetes association is seen across racial groups. Under
one scenario, gene mutations might render the β-catenin destruction complex inactive at all
times. In this situation, β-catenin would avoid destruction even in the absence of Wnt ligands,
thereby accumulating in the cytoplasm and nucleus and binding to TCF7L2 and other tran-
scription factors. These transcription factors would then act mostly as transcriptional activa-
tors, and overexpression of some of their target genes may lead to diabetes pathology. With
this type of scenario in mind, the present study was initiated to investigate genes involved in
the β-catenin destruction complex for evidence of variants that may impact risk of type 2 dia-
betes in AA women. Given the small effect sizes generally seen for common susceptibility vari-
ants, the present analyses utilized gene-based testing in an attempt to identify important genes
with multiple risk variants that might otherwise be missed in a SNP-based approach.
Methods
Study population
The data source for the current analyses was the Black Women’s Health Study (BWHS) [20], a
prospective cohort study of health and illness among U.S. black women that began in 1995
when 59,000 African American women 21–69 years of age from across the U.S. completed a
14-page postal health questionnaire. Biennial follow-up questionnaires ascertain new cases of
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type 2 diabetes and other health outcomes and update covariate data. Through 2013, follow-up
had been completed for 88% of the potential years of follow-up for the baseline cohort. The
BWHS was granted approval by the Institutional Review Board of Boston University, and all
study subjects provided written informed consent.
The accuracy of self-reported diabetes in the BWHS was previously assessed using medical
records from a sample of 227 women who reported this diagnosis [21]. Type 2 diabetes was
confirmed in 96% of these women, and another 2% were found to have other types of diabetes.
The prevalence of undiagnosed diabetes in the BWHS was also previously assessed [22], using
data from collected blood samples. Of the 1873 cohort members who provided a blood sample
in the first year of blood collection and had never reported diabetes, 120 (6.4%) had HbA1c lev-
els of 6.5% (47.5 mmol/mol) or higher, meeting criteria for diabetes [23].
About 50% of BWHS study participants provided DNA samples for analysis, and these sub-
jects were found to be highly representative of all BWHS participants across a number of fac-
tors including geographic region, education, and BMI. A case-control sample was drawn from
among participants with DNA samples for genotyping and analysis: incident cases of type 2
diabetes were selected, and one control was matched to each case on birth year (+/- 2 years)
and geographic region of residence.
We sought replication of the top associations from the BWHS in up to 8284 African Ameri-
can cases and 15,543 controls from the MEDIA (Meta-analysis of type 2 diabetes in African
Americans) Consortium, which has been previously described [9]. MEDIA includes 17 African
American type 2 diabetes GWAS.
SNP selection
The Reactome database [24,25] (http://www.reactome.org/) was used to identify 68 genes that
code for proteins involved in the Wnt pathway’s β-catenin destruction complex. Tag SNPs
were then selected for each of these 68 genes (+/- 20 kb regions surrounding them) in order to
capture (at r2 0.9) all SNPs with minor allele frequency (MAF) 5%, based on the African
populations in 1000 Genomes [26] (http://www.1000genomes.org/). In addition, tag SNPs
were selected for the +/- 100 kb region surrounding the TCF7L2 index SNP rs7903146.
Genotyping and QC
Genotyping of the selected Wnt pathway SNPs was performed in two batches totaling 6080
samples (including duplicates), as part of a custom Affymetrix Axiom array that contained
45,747 SNPs chosen for several type 2 diabetes projects. The Axiom array data underwent
extensive QC procedures carried out by Affymetrix and Slone Epidemiology Center. About
13% of samples were removed due to high missing call rates (defined as>5%), poor reproduc-
ibility, or Dish-QC values <0.6. About 17% of SNPs were removed due to poor cluster proper-
ties, high missing call rates (defined as>10%), deviation from Hardy-Weinberg equilibrium
(p<10−5 in controls), or high rates of discordant calls across duplicate samples. Only SNPs
that passed QC in both sample batches were retained for analyses. After the application of
these QC filters and the consolidation of 63 expected and confirmed duplicate sample pairs,
the full type 2 diabetes data set contained 5228 subjects (2632 cases and 2596 controls) and
38,008 SNPs, including 3430 SNPs selected for the current analyses of Wnt pathway genes.
Imputation
After prephasing the study data with SHAPEIT version 2 [27], imputation was performed
using the IMPUTE2 software [28] and the 1000 Genomes Phase 3 data as the reference panel
(5/2/2013 1000 Genomes data, October 2014 haplotype release). Imputation resulted in a total
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of 32,165 Wnt pathway SNPs with MAF 0.5% and imputation info score 0.5 for analysis.
The imputation info score used for SNP filtering was the imputation metric produced by
IMPUTE2 [29].
Association analysis
We first computed genotype principal components using the smartpca program in the
EIGENSOFT package [30], based on 18,825 genotyped and pruned common (MAF >5%)
SNPs in the full type 2 diabetes data set. The principal components of genotype were tested for
association with case status after accounting for the study covariates: age at baseline, geograph-
ical region, and genotyping batch. For all association analyses, we included principal compo-
nents that had p<0.1 in this multivariable model.
Gene-based association analyses were conducted using the adaptive rank truncated product
(ARTP) statistic [31], as implemented in the R package ARTP2 [32]. The ARTP method was
selected for its ability to optimize the number of single SNP p-values combined in each gene-
based test. According to the options we set, the ARTP2 program selected an optimal test for
each gene using between one and 10 SNPs per gene. All genotyped and imputed Wnt pathway
SNPs were input into ARTP2 for analysis. Based on the program parameters chosen, ARTP2
removed 10,445 SNPs with MAF <2% in order to eliminate low frequency, imputed SNPs.
Next, it identified pairs of SNPs with linkage disequilibrium (LD) r2 >0.8 within each gene
and removed the SNP with the lower MAF from each pair, resulting in removal of 14,918
SNPs. After implementation of the MAF and LD filters, 6802 SNPs remained for gene-based
analysis.
Single SNP association tests, required as input for gene-based testing, were performed
using logistic regression analyses of the imputed dosage genotype data. All statistical models
were adjusted for age at baseline, geographical region, genotyping batch, and genotype princi-
pal components.
Results
The results of the gene-based analyses are shown in Table 1. One gene, PSMD2, was signifi-
cantly associated with the risk of type 2 diabetes after a Bonferroni correction for the 69 genes
tested (nominal p = 2.2 x 10−4, corrected p = 0.016). One other gene, GWAS locus TCF7L2,
was associated with a nominal p<0.01 (p = 1.5 x 10−3), but this result did not survive a correc-
tion for multiple testing.
Table 2 shows the genetic variants that were included in the best models selected for genes
PSMD2 and TCF7L2. The best model selected for the PSMD2 region included nine genetic var-
iants. The best model selected for TCF7L2 included three genetic variants. The most signifi-
cantly associated variant in the TCF7L2 region was the GWAS index SNP rs7903146 (p = 1.0 x
10−5), which was associated with a ~20% increased risk of type 2 diabetes (OR 1.21, 95% CI
1.11, 1.32).
Although we had removed correlated SNPs prior to gene-based testing, the r2 threshold
used was 0.8, and there was moderate LD (0.45< r2 < 0.8) in the study sample among five of
the top six variants in the best model for PSMD2. Nevertheless, the nine variants included in
the best model for PSMD2 comprised four distinct LD groups, using r2 = 0.35 as the cutoff for
LD grouping. For TCF7L2, there was moderate LD between the top two variants in the best
model (rs7903146 and rs34872471 had r2 = 0.77), but rs114770437 was not correlated (r2 <0.05
with each of the top two SNPs).
We next reviewed SNPs in the PSMD2 and TCF7L2 regions that had been removed by
ARTP2 during pruning, in case any of the excluded SNPs were of interest due to potential
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Table 1. Associations of Wnt pathway genes with risk of type 2 diabetes in the BWHS.
Gene Chromosome Number of SNPs in the analysis P-value
PSMD2a 3 51 2.2 x 10−4
TCF7L2 10 368 1.5 x 10−3
PSMD11 17 53 0.017
CSNK1A1 5 104 0.025
FRAT1 10 62 0.033
PSME2 14 68 0.042
PSME1 14 59 0.051
PSMD4 1 40 0.095
PSMD14 2 49 0.11
PSMB1 6 67 0.12
PSMD12 17 86 0.15
PPP2R5D 6 85 0.15
PSMD10 23 11 0.15
PSME4 2 148 0.15
UBC 12 154 0.17
PSMC1 14 97 0.17
UBA52 19 96 0.18
FRAT2 10 62 0.19
PSMB10 16 33 0.19
CTNNB1 3 123 0.22
PPP2R1B 11 74 0.23
APC 5 183 0.23
PPP2R5C 14 375 0.26
PSMB6 17 105 0.27
PSMB3 17 128 0.28
PSMA2 7 53 0.30
PPP2R5E 14 381 0.30
PSMD3 17 121 0.31
PPP2R1A 19 144 0.32
PSMC2 7 65 0.33
PSMB8 6 135 0.35
PSMB9 6 141 0.36
GSK3B 3 182 0.37
BTRC 10 110 0.37
UBB 17 64 0.39
PSMD6 3 103 0.40
PSMA6 14 88 0.40
PSMC5 17 29 0.40
PSMD5 9 51 0.40
AMER1 23 14 0.40
PSMA8 18 90 0.40
PSMA7 20 65 0.41
PSMD13 11 189 0.42
PSMD1 2 121 0.42
PSMC3 11 58 0.51
PPP2CB 8 109 0.55
RPS27A 2 35 0.57
(Continued )
Novel TCF7L2 diabetes SNP identified in African American women
PLOS ONE | DOI:10.1371/journal.pone.0172577 March 2, 2017 5 / 15
functionality. In the +/- 20 kb region surrounding PSMD2, a genotyped missense SNP
rs2178403 (A/G, Met/Val), located in gene EIF4G1 and excluded from gene-based analyses
due to its high LD (r2 = 0.93) with SNP rs1879244 (Table 2), was associated with diabetes risk,
with a p-value smaller than that of the nine SNPs from the best model (p = 8.0 x 10−5). The A
allele of rs2178403 had a frequency of 6.6% in the study controls and was associated with a
30% decreased risk of type 2 diabetes (OR 0.70, 95% CI 0.58, 0.83).
Given that the most significant SNP in the PSMD2 region was potentially functional and
the top SNP in TCF7L2was the GWAS index SNP, we assessed how much of the association
signal in each region was driven by these top SNPs. We reran single variant analyses in these
two regions, conditioning on those SNPs. The results of the conditional analyses are shown in
Table 3. When we conditioned on rs2178403, three of the nine variants in the best model for
PSMD2 remained nominally significant (p<0.05). When we conditioned on rs7903146, SNP
rs114770437 in TCF7L2 remained nominally significant (p = 1.3 x 10−3). Thus, both regions
may contain multiple independent signals.
A haplotype analysis of rs7903146 and rs114770437 in TCF7L2 showed the presence of only
three of the four possible haplotypes including common haplotype rs7903146-C / rs114770437-
G (63%), and haplotypes T/G (30%) and C/A (7%). An omnibus test assessing the joint effect of
all haplotypes on the risk of type 2 diabetes was significant with p = 2.5 x 10−7. Compared to the
C/G haplotype, the T/G haplotype was associated with an 18% increased risk of type 2 diabetes
(OR 1.18, 95% CI 1.09, 1.29), and the C/A haplotype was associated with a 23% reduction in
risk (OR 0.77, 95% CI 0.66, 0.90) (Table 4).
Table 1. (Continued)
Gene Chromosome Number of SNPs in the analysis P-value
PSMA3 14 48 0.60
PSMB4 1 51 0.61
PSMA5 1 31 0.64
PSMC4 19 42 0.67
PSMD8 19 62 0.68
PSMC6 14 77 0.75
CUL1 7 218 0.81
PSMA1 11 95 0.83
PSMD7 16 46 0.83
PSMA4 15 61 0.83
PSMF1 20 194 0.84
PSMB2 1 77 0.86
PPP2R5A 1 81 0.87
AXIN1 16 378 0.89
PPP2R5B 11 59 0.90
PPP2CA 5 60 0.91
PSMB5 14 120 0.96
PSME3 17 40 0.96
PSMB11 14 107 0.96
SKP1 5 83 0.96
PSMD9 12 61 0.97
PSMB7 9 134 0.99
a Gene PSMD2 remains significant after a Bonferroni correction for the 69 genes tested (corrected p = 0.016).
doi:10.1371/journal.pone.0172577.t001
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We sought replication in the MEDIA Consortium for the top SNPs in the PSMD2 region
and for the potentially novel risk variant rs114770437 in TCF7L2. Replication data were not
available for rs114770437, but data were available for four of the nine variants in the best
model for PSMD2 (rs939317, rs9846954, rs2376524, and rs1687230). In MEDIA, these four
variants had effect estimates pointing in the same direction as BWHS, but the odds ratios were
quite small ( 1.08 for the risk alleles), and none of the associations were statistically signifi-
cant (p>0.05). Results of a meta-analysis combining BWHS and MEDIA for these four SNPs
are shown in S1 Table.
Discussion
Gene-based analyses of common variants in the vicinity of β-catenin destruction complex
genes identified an association between the PSMD2 gene region and type 2 diabetes in 2632
AA cases and 2596 AA controls. Eight of the nine variants in the best model for PSMD2 were
not located within PSMD2 itself but were instead located within other surrounding genes on
chromosome 3q27.l (EIF4G1, ECE2, and EIF2B5) (Table 2). The most significant variant in the
PSMD2 region, missense SNP rs2178403, is located within a plausible diabetes candidate gene,
EIF4G1. EIF4G1 encodes a component of the multi-subunit protein complex EIF4F. The
EIF4F complex facilitates recruitment of mRNA to the ribosome, which is the rate-limiting
step in protein synthesis. There is evidence that compromised insulin signaling in pancreatic
beta cells downregulates EIF4G1, leading to the inhibition of carboxypeptidase E (CPE) expres-
sion, with a subsequent reduction of proinsulin processing and a corresponding increase in
the levels of circulating proinsulin [34].
While EIF4G1 is a potential susceptibility gene, the results of our analyses conditioning on
rs2178403 suggest that the association signal in the PSMD2 region, if valid, may not be fully
Table 2. Genetic variants comprising the optimal models for PSMD2 and TCF7L2: associations with risk of type 2 diabetes in the BWHS.
Variant Genea Reference allele Minor allele Minor allele frequency
(%):
Imputation r2b OR (95% CI) P-value
BWHS AFR EUR
PSMD2 region
rs55808452 ECE2 GGCAAAGGGTGG - 13.0 NA NA 0.70 0.75 (0.65, 0.87) 1.0 x 10−4
rs7635741 EIF4G1 G T 8.1 3.5 22.8 0.61 0.69 (0.56, 0.84) 2.2 x 10−4
rs1879244 EIF4G1 T C 7.1 1.7 24.7 0.95 0.72 (0.60, 0.86) 2.4 x 10−4
rs939317 EIF4G1 G A 9.0 4.1 24.7 genotyped 0.76 (0.65, 0.88) 2.6 x 10−4
rs9846954 EIF4G1 T A 48.8 42.0 75.1 genotyped 0.87 (0.80, 0.94) 4.2 x 10−4
rs2376524 EIF2B5 A C 7.6 2.7 23.2 0.93 0.75 (0.63, 0.88) 5.8 x 10−4
rs9883929 PSMD2 A C 18.2 22.4 8.0 0.91 1.19 (1.07, 1.32) 9.6 x 10−4
rs1687230 ECE2 T C 16.5 11.1 37.0 genotyped 0.84 (0.75, 0.94) 2.2 x 10−3
rs72591978 EIF2B5 CA C 46.5 NA NA 1.01 0.89 (0.82, 0.96) 2.9 x 10−3
TCF7L2 region
rs7903146 TCF7L2 C T 28.2 26.0 31.7 genotyped 1.21 (1.11, 1.32) 1.0 x 10−5
rs34872471 TCF7L2 T C 33.6 31.2 31.5 1.02 1.20 (1.10, 1.30) 1.6 x 10−5
rs114770437 TCF7L2 G A 7.8 9.1 0.0 genotyped 0.73 (0.62, 0.85) 7.7 x 10−5
Abbreviations: BWHS, Black Women’s Health Study controls; AFR, 1000 Genomes Project Phase 3 African samples; EUR, 1000 Genomes Project Phase
3 European samples; OR, odds ratio (adjusted for age at baseline, geographical region, genotyping batch, and genotype principal components); CI,
confidence interval; NA, not applicable (allele frequencies are not available in 1000 Genomes).
a All SNPs are intronic.
b The imputation r2 quality metric computed by PLINK version 1.90 [33] (https://www.cog-genomics.org/plink2).
doi:10.1371/journal.pone.0172577.t002
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captured by variants in EIF4G1 alone. Furthermore, other genes in this region, including
PSMD2 itself, could be linked to diabetes pathology. The PSMD2 gene was included in this
study because of its involvement in the Wnt pathway’s β-catenin destruction complex: PSMD2
Table 3. Genetic variants comprising the optimal models for PSMD2 and TCF7L2: analyses conditioning on the top SNP in each region.








rs2178403 G A 0.70 8.0 x
10−5
NA NA excluded from gene-based analysis during
pruning
rs55808452 GGCAAAGGGTGG - 0.75 1.0 x
10−4
0.85 0.14
rs7635741 G T 0.69 2.2 x
10−4
0.92 0.71
rs1879244 T C 0.72 2.4 x
10−4
1.19 0.60
rs939317 G A 0.76 2.6 x
10−4
0.90 0.40
rs9846954 T A 0.87 4.2 x
10−4
0.90 8.6 x 10−3
rs2376524 A C 0.75 5.8 x
10−4
1.00 0.98
rs9883929 A C 1.19 9.6 x
10−4
1.17 3.3 x 10−3
rs1687230 T C 0.84 2.2 x
10−3
0.91 0.16




rs7903146 C T 1.21 1.0 x
10−5
NA NA
rs34872471 T C 1.20 1.6 x
10−5
1.08 0.36
rs114770437 G A 0.73 7.7 x
10−5
0.77 1.3 x 10−3
Abbreviations: OR, odds ratio (adjusted for age at baseline, geographical region, genotyping batch, and genotype principal components); NA, not
applicable.
a Conditional odds ratios for variants in the PSMD2 region are adjusted for age at baseline, geographical region, genotyping batch, genotype principal
components, and SNP rs2178403.
b Conditional odds ratios for variants in the TCF7L2 region are adjusted for age at baseline, geographical region, genotyping batch, genotype principal
components, and SNP rs7903146.
doi:10.1371/journal.pone.0172577.t003
Table 4. Haplotype analysis of SNPs rs7903146 and rs114770437 in TCF7L2.
rs7903146 allele rs114770437 allele Haplotype frequency (%) OR (95% CI) P-value
Cases (n = 2632) Controls (n = 2596)
C G 62.3 64.1 1.00 (reference) reference
T G 31.7 28.1 1.18 (1.09, 1.29) 5.7 x 10−5
C A 6.0 7.8 0.77 (0.66, 0.90) 1.3 x 10−3
Abbreviations: OR, odds ratio (adjusted for age at baseline, geographical region, genotyping batch, and genotype principal components); CI, confidence
interval.
doi:10.1371/journal.pone.0172577.t004
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encodes a regulatory subunit of the 26S proteasome, and it is the 26S proteasome that carries
out the actual destruction of β-catenin (as well as other ubiquitinated proteins) [35,36]. It has
been shown that a high fat diet downregulates hepatic transcription of PSMD2 in mice that are
resistant to the development of insulin resistance and non-alcoholic fatty liver disease
(NAFLD), while upregulating transcription in mice with susceptibility to developing insulin
resistance and NAFLD [37].
ECE2 is another possible susceptibility gene near PSMD2. The enzyme encoded by ECE2
converts big endothelin-1 to the vasoconstrictor endothelin-1, and is involved in the process-
ing of several neuroendocrine peptides. This enzyme may also act as a methyltransferase. A
mouse study reported an association between hyperglycemia at an early stage of autoimmune
diabetes and downregulation of ECE2 transcription in the kidneys [38]. In our study, the most
significant variant in the top model for the PSMD2 region, rs55808452, was located within an
intron of ECE2, although it should be noted that this variant was in moderate LD with several
EIF4G1 variants including missense SNP rs2178403 (r2 = 0.54).
It should be acknowledged that the association we observed for the PSMD2 region may
very well be a false positive result given that four of the top variants in this region failed to rep-
licate in the large AA sample from the MEDIA Consortium. In addition, four of the five vari-
ants that were not available in MEDIA were in moderate LD (0.7 < r2 < 0.8) with at least one
of the SNPs that failed replication. If SNPs in this region are truly associated, they likely have
small effects as represented by the MEDIA estimates. Although the MEDIA estimates were
close to the null (odds ratios between 0.92 and 0.98), they were all in the same direction as our
study. Thus, the possibility of true, small effects does exist.
Apart from the PSMD2 region, the other interesting finding from the present study con-
cerned the GWAS gene TCF7L2. SNP rs114770437 (BWHS MAF = 7.8%) was one of three vari-
ants included in the best gene-based model for TCF7L2 and was not correlated with the GWAS
index SNP rs7903146 (BWHS MAF = 28.2%). The minor A allele at rs114770437 was associated
with a 27% reduction in the risk of type 2 diabetes. The association with this SNP remained
nominally significant after control for rs7903146 (conditional OR = 0.77; p = 1.3 x 10−3). Thus,
rs114770437 may represent an independent association signal in TCF7L2 in AA populations.
SNP rs114770437 is monomorphic in 1000 Genomes European samples, and this may explain
the results of a Bayesian fine mapping analysis by the Wellcome Trust Case Control Consortium
(WTCCC), which suggested that no such secondary signal exists in TCF7L2 in Europeans [39].
In the WTCCC study, the posterior probability that rs7903146 was driving the TCF7L2 associa-
tion signal was 75%. An additional 13% of the posterior probability was accounted for by corre-
lated SNP rs34872471, the second most significant SNP in the best model for TCF7L2 in our
study. No other SNP accounted for more than 3% of the posterior probability.
Despite a respectable sample size of 2632 AA cases and 2596 AA controls, the present study
had limited power to detect individual SNP associations. Still, we replicated the association of
the TCF7L2GWAS index SNP rs7903146. The failure of TCF7L2 to achieve significance in our
gene-based analyses is likely due to the inherent power limitations of the ARTP gene-based
approach in situations where much of a gene’s association is driven by a single SNP. In our
application of the ARTP method, each gene test had to correct for having considered up to
10 SNPs. Another limitation of our study was the use of imputed genotypes for many SNPs.
However, SNPs with an imputation info score <0.5 or MAF <2% were excluded from the
association analyses in order to improve the accuracy of the data used. Lastly, non-differential
misclassification of diabetes in our sample, though likely to be small, may have resulted in
underestimation of the associations.
In summary, we observed a significant association between the PSMD2 gene region and
type 2 diabetes in women of African ancestry in a gene-based analysis. This finding opens the
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possibility that PSMD2, a gene involved in the Wnt pathway’s β-catenin destruction complex,
or another nearby gene such as EIF4G1 or ECE2, may be a susceptibility locus for type 2 diabe-
tes. It is also possible that the observed association is a false positive result, given the failed rep-
lication of a subset of the top SNPs in this region. Our analyses also suggested a possible
association signal in TCF7L2 that is independent of the GWAS index SNP rs7903146 and may
be present only in AA populations. Replication is needed in additional AA samples in order to
validate our findings.
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